Subscribe
heidi-besen
Heidi Besen / Shutterstock.com
5 June 2020Big PharmaRory O'Neill

Has the public got the taste for free medicine?

The COVID-19 pandemic has seen the fundamental principles of the IP system, normally a touchstone of advanced economies, called into question. Governments and manufacturers alike are under pressure to assure the public that IP will not be a barrier to accessing the tools needed to fight the disease.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Africa
WHO launches COVID-19 pool with 37 countries
29 May 2020   The World Health Organization has launched a COVID-19 technology pool, with 37 countries and multiple international partners and institutions rallying together to support the initiative.
Americas
Big pharma pushes back against WHO patent pool
4 June 2020   The leaders of some of the world’s largest pharma companies appear to be resistant to a World Health Organization voluntary pool aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all.
Americas
BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling
9 June 2020   Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Africa
WHO launches COVID-19 pool with 37 countries
29 May 2020   The World Health Organization has launched a COVID-19 technology pool, with 37 countries and multiple international partners and institutions rallying together to support the initiative.
Americas
Big pharma pushes back against WHO patent pool
4 June 2020   The leaders of some of the world’s largest pharma companies appear to be resistant to a World Health Organization voluntary pool aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all.
Americas
BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling
9 June 2020   Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.

More on this story

Africa
WHO launches COVID-19 pool with 37 countries
29 May 2020   The World Health Organization has launched a COVID-19 technology pool, with 37 countries and multiple international partners and institutions rallying together to support the initiative.
Americas
Big pharma pushes back against WHO patent pool
4 June 2020   The leaders of some of the world’s largest pharma companies appear to be resistant to a World Health Organization voluntary pool aimed at making vaccines, tests, treatments and other health technologies to fight COVID-19 accessible to all.
Americas
BIO 2020: IP’s vital role in COVID-19 fight, potential ‘chaos’ of pooling
9 June 2020   Concerns that IP is hindering the development of tools to fight the COVID-19 are unfounded, and now is the time that we need IP the most, according to big pharma representatives.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent